Physician profile
Michele A Burzynski
NPI 1760452684
$4,749.78
in general payments reported to CMS, 2019-2025
43 companies · $882 in 2025
The $882 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,114 · 2020: $709 · 2021: $474 · 2022: $213 · 2023: $617 · 2024: $742 · 2025: $882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,240.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $863.73 | 2019-2025 | Evenity, Repatha, Otezla |
| Pfizer INC. | $445.34 | 2019-2025 | |
| Lilly USA, LLC | $324.97 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $320.40 | 2019-2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $307.23 | 2019-2023 | Hyqvia |
| Abbvie INC. | $265.49 | 2019-2024 | Ubrelvy, Dalvance |
| Astellas Pharma US INC | $256.81 | 2019-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $232.46 | 2019-2020 | |
| Amarin Pharma, INC. | $157.55 | 2019-2021 | |
| Glaxosmithkline, LLC. | $111.68 | 2023-2025 | Shingrix, Arexvy |
| Abbott Laboratories | $98.37 | 2023-2024 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $98.23 | 2022-2025 | |
| Exact Sciences Corporation | $88.53 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.35 | 2019-2025 | Ofev, Jascayd |
| Alnylam Pharmaceuticals INC. | $78.92 | 2025 | Givlaari |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Burzynski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.